anti-NMDA receptor encephalitis
anti-NMDA receptor encephalitis
Explore linked clinical trials. Standard reference: MONDO:00210815 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, autoimmune encephalitis, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Not yet recruiting | Not stated | 2026-10-05 | NCT07858175 | |
| Efgartigimod in Anti-NMDA Receptor Encephalitis. | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-16 | NCT07822776 | |
| Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-06-09 | NCT06867991 | |
| Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Infections, Leukoencephalopathies, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Rasmussen subacute encephalitis, Skin and Connective Tissue Diseases, acute disseminated encephalomyelitis, acute transverse myelitis, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, cardiovascular disorder, central nervous system disorder, central nervous system infectious disorder, central nervous system lupus, central nervous system vasculitis, cerebrovascular disorder, connective tissue disorder, cranial nerve neuropathy, demyelinating disease, encephalitis, eye disorder, immune system disorder, meningitis, meningoencephalitis, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, myelitis, neoplasm, nervous system disorder, neurodegenerative disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, spinal cord disorder, systemic lupus erythematosus, vascular disorder, vasculitis, viral infection of central nervous system | Recruiting | Not stated | 2024-12-16 | NCT05017142 | |
| Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2024-11-20 | NCT06510283 |